1
|
Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, Lee A, Maingon P, Mäkitie A, Micciche' F, Nicolai P, O'Sullivan B, Poitevin A, Porceddu S, Składowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol 2017; 126:3-24. [PMID: 29180076 DOI: 10.1016/j.radonc.2017.10.016] [Citation(s) in RCA: 221] [Impact Index Per Article: 31.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 10/15/2017] [Accepted: 10/15/2017] [Indexed: 02/01/2023]
Abstract
PURPOSE Few studies have reported large inter-observer variations in target volume selection and delineation in patients treated with radiotherapy for head and neck squamous cell carcinoma. Consensus guidelines have been published for the neck nodes (see Grégoire et al., 2003, 2014), but such recommendations are lacking for primary tumour delineation. For the latter, two main schools of thoughts are prevailing, one based on geometric expansion of the Gross Tumour Volume (GTV) as promoted by DAHANCA, and the other one based on anatomical expansion of the GTV using compartmentalization of head and neck anatomy. METHOD For each anatomic location within the larynx, hypopharynx, oropharynx and oral cavity, and for each T-stage, the DAHANCA proposal has been comprehensively reviewed and edited to include anatomic knowledge into the geometric Clinical Target Volume (CTV) delineation concept. A first proposal was put forward by the leading authors of this publication (VG and CG) and discussed with opinion leaders in head and neck radiation oncology from Europe, Asia, Australia/New Zealand, North America and South America to reach a worldwide consensus. RESULTS This consensus proposes two CTVs for the primary tumour, the so called CTV-P1 and CVT-P2, corresponding to a high and lower tumour burden, and which should be associated with a high and a lower dose prescription, respectively. CONCLUSION Implementation of these guidelines in the daily practice of radiation oncology should contribute to reduce treatment variations from clinicians to clinicians, facilitate the conduct of multi-institutional clinical trials, and contribute to improved care of patients with head and neck carcinoma.
Collapse
Affiliation(s)
- Vincent Grégoire
- Université catholique de Louvain, St-Luc University Hospital, Department of Radiation Oncology, Brussels, Belgium.
| | - Mererid Evans
- Velindre Cancer Centre, Department of Radiation Oncology, Wales, UK
| | - Quynh-Thu Le
- Stanford University School of Medicine, Department of Radiation Oncology, USA
| | - Jean Bourhis
- CHUV and University of Lausanne, Department of Radiation Oncology, Switzerland
| | - Volker Budach
- Charité University Hospital, Department of Radio-oncology and Radiotherapy, Berlin, Germany
| | - Amy Chen
- Sun Yat-Sen University, Cancer Centre, Department of Radiation Oncology, Guangzhou, China
| | - Abraham Eisbruch
- University of Michigan Health System, Department of Radiation Oncology, Ann Arbor, USA
| | - Mei Feng
- Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China
| | - Jordi Giralt
- Vall d'Hebron University Hospital, Radiation Oncology Service, Barcelona, Spain
| | - Tejpal Gupta
- Tata Memorial Hospital, Department of Radiation Oncology, Mumbai, India
| | - Marc Hamoir
- Université catholique de Louvain, St-Luc University Hospital, Department of Head and Neck Surgery, Brussels, Belgium
| | - Juliana K Helito
- Hospital Israelita Albert Einstein, Department of Radiation Oncology, Sao Paulo, Brazil
| | - Chaosu Hu
- Fudan University Shanghai Cancer Center, Department of Radiation Oncology, China
| | - Keith Hunter
- University of Sheffield, School of Clinical Dentistry, Unit of Oral and Maxillofacial Pathology, UK
| | | | - Johannes Kaanders
- Radboud University Medical Centre, Department of Radiation Oncology, Nijmegen, The Netherlands
| | | | - Anne Lee
- University of Hong Kong and University of Hong Kong Shenzhen Hospital, Department of Clinical Oncology, Hong Kong, China
| | - Philippe Maingon
- Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Department of Radiation Oncology, Paris, France
| | - Antti Mäkitie
- University of Helsinki and Helsinki University Hospital, Department of Otorhinolaryngology - Head & Neck Surgery, Finland
| | - Francesco Micciche'
- Universita' Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Polo Scienze Oncologiche ed Ematologiche, Rome, Italy
| | - Piero Nicolai
- University of Brescia, Divisions of Otorhinolaryngology - Head and Neck Surgery, Italy
| | - Brian O'Sullivan
- University of Toronto, The Princess Margaret Hospital, Department of Radiation Oncology, Canada
| | | | - Sandro Porceddu
- Princess Alexander Hospital, Department of Radiation Oncology, Brisbane, Australia
| | | | - Silke Tribius
- Asklepios St. Georg Hospital, Hermann-Holthusen Institute for Radiotherapy, Hamburg, Germany
| | - John Waldron
- University of Toronto, The Princess Margaret Hospital, Department of Radiation Oncology, Canada
| | - Joseph Wee
- National Cancer Centre Singapore, Division of Radiation Oncology, Singapore
| | - Min Yao
- Case Western Reserve University Hospital, Department of Radiation Oncology, Cleveland, USA
| | - Sue S Yom
- University of California-San Francisco, Department of Radiation Oncology, USA
| | - Frank Zimmermann
- University Hospital Basel, Clinic of Radiotherapy and Radiation Oncology, Switzerland
| | - Cai Grau
- Aarhus University Hospital, Department of Oncology, Denmark
| |
Collapse
|